Clinical trial
Preventing Adverse Drug Events With PatientSite
NCT00140504 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00140504 |
|---|---|
| Title | Preventing Adverse Drug Events With PatientSite |
| Official title | Preventing Adverse Drug Events With PatientSite |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Agency for Healthcare Research and Quality (AHRQ) U.S. Fed Blue Cross Blue Shield Beth Israel Deaconess Medical Center |
| Status | Completed |
| Study type | Interventional |
| Conditions | Adverse Drug Event |
| Intervention type | Other |
| Interventions | Medcheck message |
| Enrollment | 800 |
| Start date | Apr 1, 2003 |
| Primary completion | Dec 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Sep 1, 2005 |
| Last update posted | Feb 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: